I am the Director of Barts Cancer Institute. My groups’ primary research interests are in the genomics and molecular pathology of pancreatic cancer and the development of oncolytic virotherapy.
We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.
The primary focus of my research is to establish a platform for a neo-antigens-based vaccine for triple-negative breast cancer and pancreatic cancer.
Our research focuses on the use of modified, replicating oncolytic Vaccinia viruses and adenoviruses armed with immune-modulatory genes such as cytokines to create a self-propagating treatment for tumours that results in long-term immunological memory to the tumour cells.
My project is focused on the identification of molecular factors affecting adenoviral therapy.
I am interested in cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses.
My project aims to identify strategies to boost host anti-cancer immune response through enhanced oncolytic efficiency of oncolytic viruses by small molecules.
My research is focused on cancer immunotherapy for pancreatic cancer, particularly immune-stimulatory molecules, armed oncolytic viruses and CAR T-cells.